Alveolar Rhabdomyosarcoma

Rhabdomyosarcoma, Alveolar is a type of cancer that starts in the muscles. It usually happens in children and young adults, often in the arms, legs, or head/neck area. This type of cancer is very aggressive and spreads quickly. While it's hard to cure, treatments like chemotherapy can help.

Condition

What people with Alveolar Rhabdomyosarcoma report

Every report comes from a Lived member, sent anonymously.

Have you tried Vincristine for Alveolar Rhabdomyosarcoma?

NameHow it went

About Alveolar Rhabdomyosarcoma

What It Is

Alveolar rhabdomyosarcoma is a type of rhabdomyosarcoma, a cancer that starts in cells that would normally develop into muscle. Rhabdomyosarcoma is the most common soft tissue sarcoma in children, and the alveolar type makes up roughly a fifth to a quarter of cases. The name comes from how the tumor looks under a microscope, with cells arranged in small spaces that resemble the air sacs (alveoli) of the lung. It occurs mostly in children and teenagers, makes up a larger share of cases in teenagers than in young children, and can also occur in adults. It most often grows in the arms or legs, the chest or trunk, the abdomen, or the area around the genitals and anus, and tumors of the hand or foot are usually this type. The most common sign is a lump or swelling that keeps growing or does not go away, which may or may not hurt. Other symptoms depend on where the tumor is and what it presses on. Alveolar rhabdomyosarcoma matters because it tends to behave more aggressively than the more common embryonal type. It is more likely to have spread to lymph nodes or other parts of the body by the time it is found, so it is always treated with intensive, combined therapy.

Causes & Risk Factors

In most people with alveolar rhabdomyosarcoma, no cause is found, and nothing a parent or patient did is known to bring it on. The tumor cells usually carry a specific genetic change that arises in the tumor itself: two genes (PAX3 or PAX7, and FOXO1) become fused together, creating an abnormal signal that drives growth. This change is acquired, not inherited, and is not passed on to children. A few inherited conditions, such as Li-Fraumeni syndrome, neurofibromatosis type 1, DICER1 syndrome and Costello syndrome, raise the risk of rhabdomyosarcoma in general. These are found less often in the alveolar type than in other types. A care team may still suggest genetic counseling, particularly when there is a family history of cancers at young ages.

How It's Diagnosed

Diagnosis starts with an examination and imaging, usually an MRI or CT scan of the lump to see its size and how it relates to nearby muscles, nerves and organs. The diagnosis itself requires a biopsy, a sample of the tumor taken with a needle or through a small incision. Because treatment depends heavily on the exact type, the sample should be reviewed by a pathologist experienced in childhood sarcomas. The laboratory also tests the tumor for the PAX3 or PAX7 and FOXO1 fusion, using techniques such as FISH or RT-PCR (tests that detect specific gene changes). About 80% of tumors that look alveolar carry this fusion. Fusion status now matters more than appearance: fusion-negative tumors behave much like the embryonal type and have a better outlook, while fusion-positive tumors are treated as higher risk. Staging tests then show whether the cancer has spread. These usually include a CT scan of the chest, a PET scan (which shows areas of active cancer throughout the body) or bone scan, bone marrow samples from the hip bones, and sampling of nearby lymph nodes. For tumors of the arms, legs or trunk, a sentinel lymph node biopsy (removing the first node the tumor drains to) is often used. The results place the cancer in a stage and a risk group, which guide how intensive treatment needs to be.

Treatment Options

Treatment is planned by a team experienced in childhood cancer, including a pediatric oncologist, surgeon and radiation oncologist. It always includes chemotherapy, because even a tumor that seems contained may have spread in amounts too small to see. Surgery, radiation or both are added to control the tumor where it started. Fusion-positive tumors are placed in at least the intermediate-risk group even when they are small and fully removed; fusion-negative tumors are grouped and treated like the embryonal type. In the United States, the standard chemotherapy is a combination called VAC (vincristine, dactinomycin and cyclophosphamide), sometimes alternated with vincristine and irinotecan. Some European treatment plans also add a longer, lower-intensity phase of maintenance chemotherapy at the end. Treatment usually continues for many months. Cancer that has spread to distant sites is high risk and is treated more intensively, often within a clinical trial. Surgery aims to remove the tumor completely when that can be done without serious loss of function or appearance. When it cannot, chemotherapy is given first to shrink the tumor, and radiation is used instead of or in addition to surgery. For a tumor in the hand or foot, for example, chemotherapy and radiation may be used rather than an operation that would affect how the hand or foot works. The main trade-offs are short-term side effects such as low blood counts, infection risk, nausea and nerve effects from vincristine, and possible long-term effects on fertility and other parts of the body. Because this cancer is rare and outcomes for higher-risk disease still need to improve, joining a clinical trial is often recommended. Targeted therapies and immunotherapies are being studied but are not yet standard.

What to Expect

Treatment is demanding. Families can expect frequent clinic visits, hospital stays for chemotherapy or fevers, and weeks of daily radiation if it is part of the plan. Fatigue, hair loss and time away from school or work are common, and nutrition, physical therapy and psychosocial support are usually part of care. The outlook varies widely and depends on whether the tumor carries the fusion, whether it has spread, the patient's age, and the tumor's size and location. In a large analysis of children with localized fusion-positive disease, about two thirds were alive four years after diagnosis, with older age and tumors larger than 5 cm linked to worse results. Fusion-negative tumors generally do better. When the cancer has already spread at diagnosis, especially to the bone marrow, long-term survival is much less common. Your care team can explain what applies to an individual case. After treatment ends, follow-up continues for years with scans and checkups to look for a return of the cancer, which happens most often in the first few years and can occur in the lungs, bones or bone marrow as well as the original site. Survivors also need long-term care for late effects of treatment, which can include problems with fertility, the teeth, eyes or digestion, changes in mood, learning or memory, and a higher risk of a second cancer.

When to Seek Help

See a doctor about a lump or swelling anywhere on the body that keeps getting bigger or does not go away, whether or not it hurts. A new lump in a hand, foot, arm or leg in a teenager deserves the same attention as one elsewhere and should not be assumed to be an injury if it persists. During chemotherapy, contact the cancer care team right away about a fever, chills or signs of infection, since chemotherapy lowers the body's ability to fight infection. After treatment, report new lumps, persistent bone pain, ongoing cough or breathlessness, or other new symptoms promptly rather than waiting for the next scheduled visit.

Questions to Ask Your Doctor

  1. 1.Does the tumor have a PAX3 or PAX7 and FOXO1 fusion, and how does that change the risk group and treatment plan?
  2. 2.What did the staging tests show about lymph nodes and spread, and what does that mean for the outlook?
  3. 3.How will the tumor's original site be treated, with surgery, radiation or both, and what effects on function or appearance should we expect?
  4. 4.Is there a clinical trial that would be appropriate, and how does it compare with standard treatment?
  5. 5.Should we discuss fertility preservation before treatment starts, and what late effects and long-term follow-up should we plan for?

Last reviewed • Oct 2026

Educational content, not medical advice.